Epilive 250 Tablet contains Levetiracetam 250mg, an antiepileptic medication primarily indicated for the treatment of partial onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in patients with epilepsy. Levetiracetam acts by modulating synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby stabilizing neuronal activity and preventing seizure propagation. Epilive 250 is typically prescribed as adjunctive therapy in adults and pediatric patients aged four years and above. The tablet should be administered orally, with dosage individualized based on clinical response and tolerability, starting at a low dose and gradually titrated to minimize adverse effects. Common side effects include dizziness, somnolence, headache, and fatigue, while serious adverse reactions are rare but may include behavioral changes or hypersensitivity reactions. Caution is advised in patients with renal impairment, and dose adjustments may be necessary. Epilive 250 should be used under strict medical supervision, with regular monitoring to assess efficacy and safety. It is contraindicated in patients with known hypersensitivity to Levetiracetam or any excipients. Patients are advised to avoid abrupt discontinuation to reduce the risk of increased seizure frequency. This medication does not replace other antiepileptic drugs unless directed by a healthcare professional.